Is Aridis Pharmaceuticals, Inc. (ARDS) a Buy, Sell, or Hold?
OTC : ARDS
Aridis Pharmaceuticals, Inc.
$0.0001 USD
$0 (0.0%)
- Volume
- 40.1K
- Average Volume
- 15.13K
- Market Capitalization
- $4.46K
- P/E Ratio
- 0.00
- Dividend Yield
- 0.00%
- Price Target
- Year High
- $0.05
- Year Low
- $0.00
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $0.32
Company Overview
OTC
Vu L. Truong
Biotechnology
Healthcare
ARDS
37
US
USD
Liquidity Metrics
-0.25
0.32
0.32
0.13
0.00
Sales & Valuation
-$
0.00
0.00
0.00
-1.56
Profitability
-$1.64
-$30.75M
0.00%
0.00%
164.69%
-209.25%
P/E Metrics
0.00
0.00
0.00
Analyst Price Target & Rating
0/5
7 Analysts
%
Financial Health Scores
-40.63
4/9
-$13.37M
$6.53M
$18.34M
-$883K
Key Metrics (TTM)
$1.26M
0.00
-0.04
0.32
164.69%
172.72%
-1637559.32%
-655351.13%
0 days
Company Executives
| Name | Title |
|---|---|
| Hasan Jafri | Chief Medical Officer |
| Eric J. Patzer | Founder & Executive Chairman |
| Vu L. Truong | Founder, Chief Executive Officer, Chief Scientific Officer & Director |
| Jeffrey J. Fessler | Acting General Counsel |
Poll Results
No votes yet today — be the first to share your view!
About Aridis Pharmaceuticals, Inc. (OTC:ARDS) Stock
Aridis Pharmaceuticals, Inc. is a late-stage biopharmaceutical company focused on the discovery and development of targeted immunotherapies, specifically employing fully human monoclonal antibodies (mAbs) to address severe, life-threatening infections. Their lead product candidate, AR-301, a fully human IgG1 mAb, is currently in pivotal Phase III trials for treating lung infections caused by Staphylococcus aureus alpha toxin. Also in their pipeline is AR-320, another fully human IgG1 monoclonal antibody designed to target S. aureus alpha toxin, aiming to treat infections stemming from both methicillin-resistant (MRSA) and methicillin-susceptible S. aureus. The company's developmental efforts extend to AR-105, a fully human IgG1 mAb in Phase II trials, which is being developed to combat the ... gram-negative bacterium P. aeruginosa. Furthermore, AR-101, a human IgM mAb, is undergoing Phase IIa clinical trials for the treatment of hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP) specifically linked to P. aeruginosa serotype O11. In earlier stages, AR-401 is in preclinical development to address infections caused by Acinetobacter baumannii, and AR-201, a fully human IgG1 mAb, is in a preclinical program targeting respiratory syncytial virus. AR-501, an anti-infective therapy, is currently in Phase I/IIa clinical trials for managing chronic lung infections in patients with cystic fibrosis. Additionally, Aridis is developing AR-712 and AR-701, a combination of two fully human IgG1 mAbs, which is in Phase I/II clinical trials for treating mild to moderate COVID-19 in non-hospitalized individuals. Aridis Pharmaceuticals, Inc. was established in 2003 and is headquartered in Los Gatos, California.
2026-05-31 09:00:00
RYBREVANT FASPRO⢠(amivantamab and hyaluronidase-lpuj) pivotal data show strong and durable responses in advanced head and neck cancer where
2026-05-29 15:00:00
RYBREVANTÂ (amivantamab-vmjw) plus LAZCLUZEÂ (lazertinib) demonstrates prolonged clinical benefit as a first-line treatment for atypical EGFR
Frequently Asked Questions
-
What is the current Aridis Pharmaceuticals, Inc. (ARDS) stock price?
-
Aridis Pharmaceuticals, Inc.(OTC:ARDS) stock price is $0.0001 in the last trading session. During the trading session, ARDS stock reached the peak price of $0.05 while $0.0001 was the lowest point it dropped to. The percentage change in ARDS stock occurred in the recent session was 0.0% while the dollar amount for the price change in ARDS stock was $0.
-
ARDS's industry and sector of operation?
-
The OTC listed ARDS is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of ARDS?
-
Hasan Jafri | Chief Medical Officer
Eric J. Patzer | Founder & Executive Chairman
Vu L. Truong | Founder, Chief Executive Officer, Chief Scientific Officer & Director
Jeffrey J. Fessler | Acting General Counsel
| -
How many employees does ARDS have?
-
Number of ARDS employees currently stands at 37. ARDS operates from 983 University Avenue, Los Gatos, CA 95032, US.
-
Link for ARDS official website?
-
Official Website of ARDS is: https://www.aridispharma.com
-
How do I contact ARDS?
-
ARDS could be contacted at phone #408 385 1742 and can also be accessed through its website. ARDS operates from 983 University Avenue, Los Gatos, CA 95032, US.
-
How many shares of ARDS are traded daily?
-
The average number of ARDS shares traded daily for last 3 months was 15.13K.
-
What is the market cap of ARDS currently?
-
The market value of ARDS currently stands at $4.46K with its latest stock price at $0.0001